2236 - Effectiveness of TBP-PI-HBr in Patients with Instrumentation, Anatomic or Functional Abnormalities: Secondary Analysis from ADAPT-PO

Saturday, October 22, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

Angela K. Talley, MD

SVP, Clinical Development
Spero Therapeutics
Cambridge, Massachusetts, United States

PE

Paul B. Eckburg, MD

Consultant
Spero Therapeutics
Cambridge, Massachusetts, United States
Ian A. Critchley, PhD

Vice President, Head
Spero Therapeutics
Cambridge, Massachusetts, United States
GM

Gary E. Moore, PhD

Moore Computing Services
Moore Computing Services, Inc.
Little Rock, Arkansas, United States
NB

Nivedita Bhatt, PhD

Spero Therapeutics
Cambridge, Massachusetts, United States
LM

Lori A. Muir, B.Sc.

Director
Spero Therapeutics
Cambridge, Massachusetts, United States
DM

David Melnick, MD

Senior Scientific Advisor
Spero Therapeutics
Cambridge, Massachusetts, United States